type I diabetes

[GeekWire] Sonoma Biotherapeutics has raised $265 million in new funding which will be used to advance its programs aiming to treat autoimmune and inflammatory conditions such as rheumatoid arthritis, type 1 diabetes, and IBD.

[Cell Reports] Type 1 diabetes (T1D) patients had a lower serum MOTS-c level than did healthy controls. Furthermore, MOTS-c reduced T cell activation by alleviating T cells from the glycolytic stress in T1D patients, suggesting therapeutic potential.

[Cell Host & Microbe] The authors found that maternal cecal microbiota transfer to NOD mice after early-life antibiotic perturbation largely rescued the induced type 1 diabetes enhancement.

[Provention Bio, Inc.] Provention Bio, Inc. announced that the FDA has issued a CRL for the company' BLA for teplizumab for the delay of clinical type 1 diabetes in at-risk individuals.

[JCI Insight] Investigators showed that macrophages contributed significantly to the loss of β-cells and the subsequent development of hyperglycemia. Depletion or inhibition of 12-LOX in this model resulted in reduced macrophage infiltration into islets and the preservation of β-cell mass.

[Advanced Science] The design considerations and functional requirements of macroencapsulation systems are reviewed, specifically for stem-cell derived islets, highlighting distinct design parameters.